Show simple item record

dc.contributor.authorLópez Méndez, Tania Belén
dc.contributor.authorSánchez Álvarez, José Miguel
dc.contributor.authorTrionfetti, Flavia
dc.contributor.authorPedraz Muñoz, José Luis ORCID
dc.contributor.authorTripodi, Marco
dc.contributor.authorCordani, Marco
dc.contributor.authorStrippoli, Raffaele
dc.contributor.authorGonzález Valdivieso, Juan
dc.date.accessioned2023-03-27T16:59:09Z
dc.date.available2023-03-27T16:59:09Z
dc.date.issued2023-03
dc.identifier.citationCell and Bioscience 13(1) : (2023) // Article ID 44es_ES
dc.identifier.issn2045-3701
dc.identifier.urihttp://hdl.handle.net/10810/60519
dc.description.abstractIn recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators.es_ES
dc.description.sponsorshipWork in the laboratories of the authors is funded by grants from the Italian Ministries for Health (Ricerca Corrente) to M.T., from Education, University and Research (MIUR; 000003_17_MAP_STRIP and FISR 2020-Covid FISR2020IP_03366) to R.S; and from the Spanish Ministerio de Ciencia e Innovación (PID2021-128106NA-I00). M.C. is currently a recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2021-031003-I) and was funded by “Maria Zambrano” contract from Spanish Ministry of Universities and Complutense University of Madrid. M.S-A is recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2020-029690-I).es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2021-128106NA-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/RYC2021-031003-Ies_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/RYC2020-029690-Ies_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcanceres_ES
dc.subjectnanomedicinees_ES
dc.subjectbiomaterialses_ES
dc.subjectclinical trialses_ES
dc.subjectautophagyes_ES
dc.titleNanomedicine for autophagy modulation in cancer therapy: a clinical perspectivees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the dataes_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-023-00986-9es_ES
dc.identifier.doi10.1186/s13578-023-00986-9
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data
Except where otherwise noted, this item's license is described as © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data